期刊文献+

尿激酶/尿激酶受体结构研究进展 被引量:4

Progress in the Structural Study of Urokinase Receptor System
下载PDF
导出
摘要 尿激酶是纤溶酶原的主要激活物之一。近年来的研究工作发现,尿激酶及其受体-尿激酶 受体-在其他多种生理和病理过程中也发挥了重要作用,包括了创伤愈合、组织再生、细胞迁移、 特别是癌症转移和血管生成等多种生理和病理过程。除了其配体尿激酶外,尿激酶受体还能结 合其他多种蛋白质,包括了玻璃体结合蛋白、LDL受体蛋白,及多种整合素等蛋白质,这些蛋白 质-蛋白质相互作用是尿激酶-尿激酶受体系统生物作用的结构基础,是目前的一个重要研究方 向。结合作者的工作描述了该体系的结构研究现状。 uPA is one of the primary activator of plasminogen, playing important role in clot lysis. Studies in recent years illustrate that uPA and its receptor (uPAR) also affect other physiological and pathophysilogical processes, including wound healing, tissue regeneration, cell migration, angiogenesis, and cancer biology. Besides its uPA ligand, uPAR can also bind, with high affinity, with vitronectin, LDL receptor protein (LRP), and several intergrin proteins. These protein-protein interactions are the basis of uPA/uPAR biological functions, and are important research directions currently actively pursued. The authors oresent the current research status of theirs and others in this area.
出处 《中国生物工程杂志》 CAS CSCD 北大核心 2005年第B04期144-147,共4页 China Biotechnology
基金 中科院百人计划结构化学国家重点实验室基金国家自然科学基金(30430190)
关键词 尿激酶 尿激酶受体 晶体结构 Urokinase Urokinase receptor Crystal structure
  • 相关文献

参考文献25

  • 1Vassalli J D, Baccino D, Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol, 1985,100 (1) :86 - 92.
  • 2Vassalli J D, Sappino A P, Belin D. The plasminogen activator/plasmin system. J Clin Invest, 1991,88 (4) :1067 - 1072.
  • 3Yamamoto K, Loskutoff D J. Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type hut not tissue-type plasminogen activator. J Clin Invest, 1996,97 (11) :2440 - 2451.
  • 4Davis J,Wagner M R, Zhang W, et al. Amyloid beta-protein stimulates the expression of urokinase-type plasminogen activator(uPA) and its receptor (uPAR) in human cerebrovascular smooth muscle cells. J Biol Chem, 2003,278 (21) : 19054 - 19061.
  • 5De Bock C E, Wang Y. Clinical significance of urokina-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev,2004,24 (1) : 13 - 39.
  • 6Pierga J Y, Bonneton C, Magdelenat H, et al. Real-time quantitative PCR determination of urokinase-type plasminogen activator receptor (uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patients. Int J Cancer,2O04.
  • 7Wilhelm O, Weidle U, Hohl S, et al. Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA).Inhibition of proliferation and invasion of human ovarian cancer cells. FEBS Lett, 1994,337 (2) : 131 - 134.
  • 8Bruse C, Radu D, Bergqvist A. In situ localization of mRNA for the fibrinolytic factors uPA. PA1-I and uPAR in endometriotic and endometrial tissue. Mol Hum Reprod, 2004,10 (3):159 - 166.
  • 9Uszynski M, Perlik M, Uszynski W, et al. Urokinase plasminogen activator (uPA) and its receptor (uPAR) in gestational tissues:Measurements and clinical implications. Eur J Obstet Gynecol Reprod Biol, 2004,114 (1) :54 - 58.
  • 10Xing R H, Rabbani S A. Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth and metastasis. Int J Cancer, 1996,67 (3) :423 - 429.

同被引文献64

引证文献4

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部